Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia

Cancer Chemother Rep. 1972 Aug;56(4):535-42.

Authors

R R Ellison, B Hoogstraten, J F Holland, R N Levy, S L Lee, R T Silver, L A Leone, T Cooper, R A Oberfield, A Ten Pas, J Blom, C Jacquillat, F Haurani

PMID: 4507688

No abstract available

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Bone Marrow / drug effects
Humans
Leukemia / drug therapy*
Leukemia, Lymphoid / drug therapy
Leukemia, Lymphoid / mortality
Leukemia, Monocytic, Acute / drug therapy
Leukemia, Monocytic, Acute / mortality
Mercaptopurine / administration & dosage*
Mercaptopurine / adverse effects
Mercaptopurine / pharmacology
Mercaptopurine / therapeutic use
Methotrexate / administration & dosage*
Methotrexate / adverse effects
Methotrexate / pharmacology
Methotrexate / therapeutic use
Prognosis
Remission, Spontaneous
Time Factors

Substances

Adrenal Cortex Hormones
Mercaptopurine
Methotrexate